| Name | Title | Contact Details |
|---|
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.
Fairmont General Hospital is a private, non-profit, community hospital founded in 1939. The hospital provides a wide variety of patient services and is accredited by the Joint Commission and the American College of Surgeons Commission on Cancer.
Electrophoresis Equipment including Vertical Electrophoresis(Vertical Gel), Horizontal Electrophoresis(Horizontal Gels), Precast Gels, SDS Page, PCR Workstations, DNA Sequencing, and more. Products for Molecular Separations. CBS Scientific Company.
Manitoba Institute of Child Health is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts.